DECIDE

Developing and Evaluating GRADE Communication strategies to support Informed Decisions and practice based on Evidence

Strategies for collaboration among European guideline developers and health technology assessment agencies

Jan Brozek¹, Nancy Santesso¹, Reem Mustafa², Yngve Falck-Ytter³, Lisa Schell⁴, Gerd Antes⁴, Joerg Meerpohl⁴, Holger Schünemann¹

¹Department of Clinical Epidemiology & Biostatistics, McMaster University ²Department of Internal Medicine, University of Missouri Kansas City ³Case Western Reserve University School of Medicine ⁴German Cochrane Centre, University Medical Centre Freiburg

a n A

Guideline Development Tool Guideline development from start to finish

GRADE KSA D	IVT Dia	tosis		۹,	* 0 *
TASKS					
В . ТЕАН	1	Tejan Baldeh			e
MEMBERS	2	Halger Schunemann			e
CONFLICTS OF INTEREST	3	Wajtek Wierolach			e
SCOPE	4	Gren names: Jan	Last name: Brozek		ы
DOCUMENT SECTIONS					
COMPARISONS		E-mail address: 1_baldeh@hotmail.com			1
DISSEMINATION		,	Add team member		





	▼ Sho	uld clinical asse	essment of the	he pretest v	s. diagnost	ic strategy i	without clinical assess	ment of the pretest b	e used for diagnosin	g firs 📌 Expla		0.	
TASKS	Quality assessment							Summary of findings					
TEAM		Analy approximit						NP of patients disgnastic strategy		E	ffect		
SCOPE DOCUMENT SECTIONS	NP of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	clinical assessment of the pretest	without clinical assessment of the	Relative (95% CI)	Absolute (95% CI)	Quality	Importance
	Venous t	hromboembolism (fellow up: 3 m	onths)									1
COMPARISONS	1	randomised trial	serious 2	not serious 1	not serious d	not serious	not serious	4/798 (0.5)% Å	4/798 (0.5)% \$	not estimable	not estimable 1	⊕⊕⊕⊖ MODERATE	
	Death (follow up: 3 months)												
	1	randomised trial	serious 2	not serious 1	not serious ±	not serious	not serious	15/860 (1.7)%	15/863 (1.7)%	not estimable	not estimable	CORATE	
	Hajor bla	Major bleeding											I
	1	randomised trial	serious 2	not serious 2	not serious 4	not serious	not serious	2/860 (0.2)%	1/863 (0.1)%	not estimable	not estimable	@@@@O MODERATE	
	D-simertesting											1	
NALYSES	1	randomised trial	serious 2	not serious	not serious d	not serious	not serious	668/860 (77.7)%	859/863 (99.5)%	not estimable	not estimable	@@@@O MODERATE	
	Ultrason	ography											1
DISSEMINATION	1	randomised trial	serious 2	not serious	not serious ±	not serious	not serious	438/860 (50.9)%	506/863 (58.6)%	not estimable	not estimable	@@@@O MCCERATE	INPORTANT
DISSEMINATION	Ultrasen	ography in outpatio	ents with a Low	v clinical pre-t	est probabilit								1
	1	randomised trial	serious 2	not serious 2	not serious ±	not serious	not serious	72/360 (20.0)%	137/334 (41.0)%	not estimable	not estimable	@@@O MODERATE	INPORTANT
							Ad	doutcome					







Out of 1000 peop (th a 40% (400 per 1000) Meetihood of havin

158(30%)

560 do ori

28(5%)

532(199%)

True negatives (correct diagnosis)

440

282(64%)





This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 258583.